GENEREX BIOTECHNOLOGY CORP
Other · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|---|
| Revenue | — | $6.2M | $703,244 | — | — | — |
| Operating income | −$17.9M | −$24.3M | −$2.5M | −$1.6M | −$1.9M | −$3.6M |
| Net income | −$34.2M | −$11.0M | $35.9M | −$76.8M | −$3.2M | −$2.2M |
| Total assets | $45.4M | $49.6M | $6.6M | $10.1M | $26,274 | $2.2M |
| Total liabilities | $53.3M | $37.9M | $50.2M | $90.0M | $11.2M | $10.5M |
| Equity | −$12.0M | $7.7M | −$43.6M | −$79.9M | −$11.2M | −$8.3M |
| EPS (diluted) | $-0.46 | $-0.14 | $14.02 | $-70.92 | $-3.69 | — |
| Shares out. | 107.9M | 44.2M | 1.1M | 1.1M | 908.5M | 859.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- —
- Net margin
- —
- Return on equity
- 286.3%
- Return on assets
- −75.4%
- Return on capital (ROCE)
- −447.1%
- Liabilities / assets
- 117.4%
- Debt / equity
- —
- Book value / share
- $-0.11
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Altman Z″ (distress)
- -41.16distress
- Accruals / assets
- −61.9%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Nov 1, 2021
- NT 10-Qmissed a reporting deadline ↗Jun 14, 2021
- NT 10-Qmissed a reporting deadline ↗Dec 15, 2020
- NT 10-Kmissed a reporting deadline ↗Oct 29, 2020
- NT 10-Qmissed a reporting deadline ↗Jun 15, 2020
- NT 10-Qmissed a reporting deadline ↗Mar 16, 2020
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Haines Harold Gray | Dec 4, 2018 | Buy | 555 | $2.10 |
| Haines Harold Gray | Dec 7, 2018 | Buy | 300 | $1.03 |
| Brusegard DavidOfficer — Chief Operating Officer | Feb 16, 2016 | Option exercise | 1.7M | $0.00 |
| Fletcher MarkOfficer — President & CEO | Feb 16, 2016 | Option exercise | 4.4M | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Other material eventJul 23, 2021
- Entered a material agreement · New financial obligation · Unregistered equity saleJul 21, 2021
- Other material eventMay 12, 2021
- Other material eventApr 29, 2021
- Other material eventApr 27, 2021
- Entered a material agreement · New financial obligation · Unregistered equity saleFeb 23, 2021
- Other material eventFeb 19, 2021
- Other material eventFeb 10, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.